Fruquintinib Combined With TAS102 for Advanced Gastric Cancer
This is a prospective, single-center, open, single-arm clinical study to observe and evaluate the efficacy and safety of Fruquintinib combined with TAS102 for second-line treatment of advanced gastric cancer.
| Condition(s) | Gastric Cancer |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | This is a prospective, single-center, open, single-arm clinical study to observe and evaluate the efficacy and safety of Fruquintinib combined with TAS102 for second-line treatment of advanced gastric cancer. |
| Who can participate | Inclusion Criteria: 1. Age ≥18 years old. 2. The ECOG score is 0-1 and does not deteriorate within 7 days. 3. Patients with histologically confirmed, metastatic, or unresectable locally advanced gastric cancer or GEJ adenocarcinoma. 4. Previously received one systemic chemotherapy regimen for this cancer and progressed; Or have received adjuvant chemotherapy, but have disease progression or recurrence within 6 months after the end of treatment. 5. Measurable lesions that meet RECIST 1.1 criteria. 6. Have adequate organ and bone marrow function, laboratory tests meet the following requirements: 1. HGB≥90g/L; 2. NEUT≥1.5×10\^9/L; 3. PLT ≥80×10\^9/L; 4. TBIL≤1.5 times upper limit of normal value (ULN); 5. ALT and AST≤2.5 x ULN; In liver metastasis, ALT and AST≤5×ULN; 6. Endogenous creatinine |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Tianjin Medical University Cancer Institute and Hospital |
| Locations | Tianjin, Tianjin Municipality, China |
| Start date | 2023-11-10 |
| NCT ID | NCT06102785 |
| Official listing | https://clinicaltrials.gov/study/NCT06102785 |